How to buy Assertio Therapeutics stock (ASRT)

Assertio Therapeutics is a drug manufacturers - specialty & generic business based in the US. Assertio Therapeutics shares (ASRT) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.93 – a decrease of 3.6% over the previous week. Assertio Therapeutics employs 53 staff and has a trailing 12-month revenue of around $125.8 million.

Our top picks for where to buy Assertio Therapeutics stock

Buy Assertio Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Assertio Therapeutics stock price (NASDAQ: ASRT)

Use our graph to track the performance of ASRT stocks over time.

Assertio Therapeutics shares at a glance

• Key figures

Information last updated 2024-12-11.

Latest market close	$0.93
52-week range	$0.73 - $1.80
50-day moving average more info button	$1.13
200-day moving average more info button	$1.09
Wall St. target price	$3.15
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-4.94

Is it a good time to buy Assertio Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Assertio Therapeutics price performance over time

Historical closes compared with the close of $0.92 from 2024-12-13

1 week (2024-12-10)	-3.75%
1 month (2024-11-18)	9.30%
3 months (2024-09-17)	-29.23%
6 months (2024-06-17)	-12.38%

1 year (2023-12-15)	-11.54%
2 years (2022-12-16)	-74.86%
3 years (2021-12-17)	1.91
5 years (2019-12-17)	5.12

Is Assertio Therapeutics stock undervalued or overvalued?

Valuing Assertio Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Assertio Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Assertio Therapeutics's PEG ratio

Assertio Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.2. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Assertio Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Assertio Therapeutics's EBITDA

Assertio Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $16.5 million.

The EBITDA is a measure of a Assertio Therapeutics's overall financial performance and is widely used to measure a its profitability.

Assertio Therapeutics financials

Revenue TTM	$125.8 million
Gross profit TTM	$138.3 million
Return on assets TTM	-1.44%
Return on equity TTM	-42.36%
Profit margin	-54.46%
Book value	$1.38
Market Capitalization more info button	$81.8 million

TTM: trailing 12 months

Assertio Therapeutics share dividends

We're not expecting Assertio Therapeutics to pay a dividend over the next 12 months.

Have Assertio Therapeutics's shares ever split?

Assertio Therapeutics's shares were split on a 1:4 basis on 17 May 2021 . So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Assertio Therapeutics shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Assertio Therapeutics shares which in turn could have impacted Assertio Therapeutics's share price.

Assertio Therapeutics share price volatility

Over the last 12 months, Assertio Therapeutics's shares have ranged in value from as little as $0.7324 up to $1.798. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Assertio Therapeutics's is 0.835. This would suggest that Assertio Therapeutics's shares are less volatile than average (for this exchange).

Assertio Therapeutics overview

Assertio Holdings, Inc. , a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020.

Frequently asked questions

null
What percentage of Assertio Therapeutics is owned by insiders or institutions?
Currently 2.473% of Assertio Therapeutics shares are held by insiders and 38.466% by institutions. How many people work for Assertio Therapeutics?
Latest data suggests 53 work at Assertio Therapeutics. When does the fiscal year end for Assertio Therapeutics?
Assertio Therapeutics's fiscal year ends in December. Where is Assertio Therapeutics based?
Assertio Therapeutics's address is: 100 South Saunders Road, Lake Forest, IL, United States, 60045 What is Assertio Therapeutics's ISIN number?
Assertio Therapeutics's international securities identification number is: US04546C2052 What is Assertio Therapeutics's CUSIP number?
Assertio Therapeutics's Committee on Uniform Securities Identification Procedures number is: 04545L107